Estimating Global Burden of Disease due to congenital anomaly: An analysis of European data

Breidge Boyle, Marie-Claude Addor, Larraitz Arriola, Ingeborg Barisic, Fabrizio Bianchi, Melinda Csaky-Szunyogh, Hermien E. K. de Walle, Carlos Matias Dias, Elizabeth Draper, Miriam Gatt, Ester Garne, Martin Haeusler, Karin Kallen, Anna Latos-Bielenska, Bob McDonnell, Carmel Mullaney, Vera Nelen, Amanda J. Neville, Mary O'Mahony, Annette Queisser-WahrendorfHanitra Randrianaivo, Judith Rankin, Anke Rissmann, Annukka Ritvanen, Catherine Rounding, David Tucker, Christine Verellen-Dumoulin, Diana Wellesley, Ben Wreyford, Natalia Zymak-Zakutnia, Helen Dolk*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

84 Citaten (Scopus)
257 Downloads (Pure)


Objective To validate the estimates of Global Burden of Disease (GBD) due to congenital anomaly for Europe by comparing infant mortality data collected by EUROCAT registries with the WHO Mortality Database, and by assessing the significance of stillbirths and terminations of pregnancy for fetal anomaly (TOPFA) in the interpretation of infant mortality statistics.

Design, setting and outcome measures EUROCAT is a network of congenital anomaly registries collecting data on live births, fetal deaths from 20 weeks' gestation and TOPFA. Data from 29 registries in 19 countries were analysed for 2005-2009, and infant mortality (deaths of live births at age

Results According to WHO, 17%-42% of infant mortality was attributed to congenital anomaly. In 11 EUROCAT countries, average infant mortality with congenital anomaly was 1.1 per 1000 births, with higher rates where TOPFA is illegal (Malta 3.0, Ireland 2.1). The rate of stillbirths with congenital anomaly was 0.6 per 1000. The average TOPFA prevalence was 4.6 per 1000, nearly three times more prevalent than stillbirths and infant deaths combined. TOPFA also impacted on the prevalence of postneonatal survivors with non-lethal congenital anomaly.

Conclusions By excluding TOPFA and stillbirths from GBD years of life lost (YLL) estimates, GBD underestimates the burden of disease due to congenital anomaly, and thus declining YLL over time may obscure lack of progress in primary, secondary and tertiary prevention.

Originele taal-2English
Pagina's (van-tot)F22-F28
Aantal pagina's7
Nummer van het tijdschrift1
StatusPublished - jan-2018

Citeer dit